# Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

> **NCT06693128** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib
- **DRUG:** S-1, Oxaliplatin

## Key facts

- **NCT ID:** NCT06693128
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2026-05-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06693128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06693128, "Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06693128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*